Want to see MBX full AI Analyst Report?
Top Page
MBX Biosciences, Inc.
(NASDAQ:MBX)
Select Model
Select Model
Rating:60Neutral
Price Target:
$70.00
▲(4.85% Upside)
Action:Reiterated
Date:08/28/26
The score is held back primarily by weak financial performance (no revenue and significant, worsening losses with continued cash burn). Offsetting this are a strong, low-debt balance sheet and positive corporate milestones (Phase 3 initiation and supportive clinical data), while technicals are supportive and valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Phase 3 Progress
Starting a registrational Phase 3 trial is a major development milestone that moves canvuparatide toward potential commercialization. The global study and commercial-use device support a credible path to testing efficacy, safety and market readiness.
Negative Factors
No Commercial Revenue
MBX remains a development-stage biotech with no commercial revenue or operating scale. Widening net and operating losses leave future value dependent on clinical execution and eventual product approval, while the absence of revenue limits visibility into sustainable economics.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 Progress
Starting a registrational Phase 3 trial is a major development milestone that moves canvuparatide toward potential commercialization. The global study and commercial-use device support a credible path to testing efficacy, safety and market readiness.
Read all positive factors
MBX Biosciences, Inc. (MBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.30B
Dividend YieldN/A
Average Volume (3M)963.99K
Price to Earnings (P/E)―
Beta (1Y)1.97
Revenue GrowthN/A
EPS Growth-4.40%
CountryUS
Employees63
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.40
Shares Outstanding48,160,095
10 Day Avg. Volume790,850
30 Day Avg. Volume963,994
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)3.12
Price to Sales (P/S)0.00
P/FCF Ratio-14.06
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$89.33Price Target Upside33.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.14
Revenue Forecast (FY)N/A
MBX Biosciences, Inc. Business Overview & Revenue Model
Company Description
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid ho...
MBX Biosciences, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -224.00K | -248.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -107.88M | -86.72M | -61.68M | -32.41M | -25.70M |
| Net Income | -104.29M | -86.97M | -61.92M | -32.56M | -26.14M |
Balance Sheet | |||||
| Total Assets | 435.91M | 385.14M | 268.54M | 84.18M | 45.09M |
| Cash, Cash Equivalents and Short-Term Investments | 418.58M | 373.70M | 262.15M | 80.68M | 42.46M |
| Total Debt | 3.34M | 596.00K | 171.00K | 324.00K | 461.00K |
| Total Liabilities | 26.37M | 15.92M | 11.09M | 156.65M | 87.70M |
| Stockholders Equity | 409.54M | 369.22M | 257.44M | -72.47M | -42.60M |
Cash Flow | |||||
| Free Cash Flow | -85.20M | -81.88M | -55.55M | -32.11M | -23.56M |
| Operating Cash Flow | -82.67M | -79.95M | -54.68M | -31.98M | -23.12M |
| Investing Cash Flow | -180.80M | -83.70M | -160.59M | -30.93M | -11.41M |
| Financing Cash Flow | 278.02M | 189.59M | 234.10M | 69.22M | 46.06M |
MBX Biosciences, Inc. Risk Analysis
MBX Biosciences, Inc. disclosed 93 risk factors in its most recent earnings report. MBX Biosciences, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MBX Biosciences, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $3.30B | -27.82 | -26.01% | ― | ― | -4.40% | |
59 Neutral | $2.80B | -7.74 | -76.09% | ― | -58.40% | -31.99% | |
57 Neutral | $1.59B | -10.93 | -46.39% | ― | ― | -33.90% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | $99.97M | -0.31 | 108.75% | ― | 32.43% | 7.40% |
* General Sector Average
MBX
MBX Biosciences, Inc.
66.76
52.49
367.83%
GOSS
Gossamer Bio
0.17
-2.23
-92.79%
NRIX
Nurix Therapeutics
26.71
17.30
183.85%
TYRA
Tyra Bioscience
26.22
13.85
111.96%
MBX Biosciences, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
MBX Biosciences Begins Pivotal Phase 3 Canvuparatide Trial
Positive
Aug 27, 2026
On August 27, 2026, MBX Biosciences announced that the first patient had been dosed in its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide in adults with chronic hypoparathyroidism. The global, multicenter registrational study will enr...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
MBX Biosciences Advances Canvuparatide and Obesity Pipeline
Positive
Aug 6, 2026
MBX Biosciences reported its second-quarter 2026 results on August 6, 2026, highlighting sustained one-year data for once-weekly canvuparatide in chronic hypoparathyroidism and the start of recruitment for the global oPTimize Phase 3 pivotal trial...
Executive/Board Changes
MBX Biosciences Announces CEO Transition and Leadership Updates
Neutral
Jul 13, 2026
MBX Biosciences announced that Chief Executive Officer and director Kent P. Hawryluk will step down from both roles effective July 13, 2026, under a separation agreement that includes 12 months of salary, continued health coverage, a target bonus,...
Business Operations and StrategyProduct-Related Announcements
MBX Biosciences unveils positive Phase 2 canvuparatide results
Positive
Jun 12, 2026
On June 12, 2026, MBX Biosciences reported full 12-week Phase 2 Avail data and one-year open-label extension results for once-weekly canvuparatide in adults with chronic hypoparathyroidism. The therapy achieved a 63% responder rate versus 31% for ...
Executive/Board ChangesShareholder Meetings
MBX Biosciences Shareholders Approve Directors and Auditor
Positive
Jun 5, 2026
MBX Biosciences, Inc., a publicly traded biopharmaceutical company with 47,570,485 outstanding common shares as of April 10, 2026, held its 2026 annual meeting of stockholders on June 4, 2026. Shareholders considered board elections and the select...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.